3
Announcements
Trials
Browse
Landscape
Status
No longer available
1
Approved for marketing
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
207
Observational
6
Expanded_access
2
Sponsor
Cancer Type
Plasma cell
2
Conditions
Multiple Myeloma
2
Recurrence
1
Interventions
elotuzumab
4
Bortezomib
4
Lenalidomide
3
Dexamethasone
3
talquetamab
2
selinexor
2
pomalidomide
2
carfilzomib
2
Panobinostat
2
venetoclax
1
ulocuplumab
1
plerixafor
1
idecabtagene vicleucel
1
fludarabine phosphate
1
daratumumab
1
ceritinib
1
belantamab mafodotin
1
Whole-Body Irradiation
1
Tacrolimus
1
Prednisone
1
Mycophenolic Acid
1
Melphalan
1
Cytarabine
1
Crizotinib
1
Cord Blood Stem Cell Transplantation
1
Calcium Dobesilate
1
Busulfan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Expanded_access
×
pomalidomide
×
Plasma cell
×
Clear all
NCT01632826
2019-11-12
PEXIUS
Celgene
Approved for marketing
NCT03723096
2018-12-20
Expanded Access for CC-4047
Celgene
No longer available